Yanetal. BMCBioinformatics 2019,20(Suppl15):538
https://doi.org/10.1186/s12859-019-3093-x
RESEARCH OpenAccess
DDIGIP:predictingdrug-drug
interactionsbasedonGaussianinteraction
profilekernels
ChengYan1,2,GuihuaDuan1,YiPan3,Fang-XiangWu4andJianxinWang1*
From14thInternationalSymposiumonBioinformaticsResearchandApplications(ISBRA’18)
Beijing,China.8-11June2018
Abstract
Background: Adrug-drug interaction(DDI)isdefinedasadrugeffectmodifiedbyanotherdrug,whichisvery
commonintreatingcomplexdiseasessuchascancer.ManystudieshaveevidencedthatsomeDDIscouldbean
increaseoradecreaseofthedrugeffect.However,theadverseDDIsmayberesultinseveremorbidityandeven
moralityofpatients,whichalsocausesomedrugstowithdrawfromthemarket.Asthemulti-drugtreatmentbecomes
moreandmorecommon,identifyingthepotentialDDIshasbecomethekeyissueindrugdevelopmentanddisease
treatment.However,traditionalbiologicalexperimentalmethods,includinginvitroandvivo,areverytime-consuming
andexpensivetovalidatenewDDIs.Withthedevelopmentofhigh-throughputsequencingtechnology,many
pharmaceuticalstudiesandvariousbioinformaticsdataprovideunprecedentedopportunitiestostudyDDIs.
Result:Inthisstudy,weproposeamethodtopredictnewDDIs,namelyDDIGIP,whichisbasedonGaussian
InteractionProfile(GIP)kernelonthedrug-druginteractionprofilesandtheRegularizedLeastSquares(RLS)classifier.
Inaddition,wealsousethek-nearestneighbors(KNN)tocalculatetheinitialrelationalscoreinthepresenceofnew
drugsviathechemical,biological,phenotypicdataofdrugs.WecomparethepredictionperformanceofDDIGIPwith
othercompetingmethodsviathe5-foldcrossvalidation,10-crossvalidationanddenovodrugvalidation.
Conlusion: In 5-foldcrossvalidationand10-crossvalidation,DDRGIPmethodachievestheareaundertheROC
curve(AUC)of0.9600and0.9636whicharebetterthanstate-of-the-artmethod(L1Classifierensemblemethod)of
0.9570and0.9599.Furthermore,fornewdrugs,theAUCvalueofDDIGIPindenovodrugvalidationreaches0.9262
whichalsooutperformstheotherstate-of-the-artmethod(Weightedaverageensemblemethod)of0.9073.Case
studiesandtheseresultsdemonstratethatDDRGIPisaneffectivemethodtopredictDDIswhilebeingbeneficialto
drugdevelopmentanddiseasetreatment.
Keywords: Drug,Drug-druginteraction,Gaussianinteractionprofile,RLS
*Correspondence: jxwang@mail.csu.edu.cn
1SchoolofComputerScienceandEngineering,CentralSouthUniversity,932
SouthLushanRd,410083,ChangSha,China
Fulllistofauthorinformationisavailableattheendofthearticle
©TheAuthor(s).2019 OpenAccess ThisarticleisdistributedunderthetermsoftheCreativeCommonsAttribution4.0
InternationalLicense( http://creativecommons.org/licenses/by/4.0/ ),whichpermitsunrestricteduse,distribution,and
reproductioninanymedium,providedyougiveappropriatecredittotheoriginalauthor(s)andthesource,providealinktothe
CreativeCommonslicense,andindicateifchangesweremade. TheCreativeCommonsPublicDomainDedicationwaiver
(http://creativecommons.org/publicdomain/zero/1.0/ )appliestothedatamadeavailableinthisarticle,unlessotherwisestated.Yanetal. BMCBioinformatics 2019,20(Suppl15):538 Page2of10
Background
Drug-drug interactions (DDI) is defined as that a drug
affects the efficacy of another drug when multi-drugs are
adopted in the treatment of a disease [ 1]. DDIs can lead
to change systemic exposure and result in variations in
drug responses, which can improve the drugs efficiency
andthelifequalityofillnesses[ 2].However,DDIsalsocan
cause serious adverse effects, drug withdrawal from the
market and even the patient morality [ 3,4]. Meanwhile,
with the medical technology development and personal-ized medical requirements, more and more patients were
simultaneously treated by multi-drugs and between 2009
and2012,38.1%ofU.S.adultsaging18-44yearsusedthree
or more prescription drugs during a 30 day time period
[5–7]. Therefore, identifying the potential DDIs has
become a major issue in drug development and practice
process.
With the high-throughput sequencing technology
development, many databases related to drugs have been
constructed.DrugBankdatabasecanprovidedrugtargets,
drug enzymes, drug transporters and DDIs, which arewidelyusedinstudyingdrug-targetassociationsanddrug
repositioning [ 8–10]. PubChem Compound database
contains the chemical substructures and their biologi-c a lt e s tr e s u l t s[ 11]. In addition, SIDER and OFFSIDES
databases include drug side effects and "off-label" side
effects, respectively [ 12,13]. KEGG database contains
drug pathways and chemical substructures [ 14]. TWO-
SIDES database contains the DDIs based on the adverse
event reports in the AERS (adverse effect reactions)
[13,15].
The above mentioned databases related to drugs were
extracted from the published literature and reports with
experimental validation, and could provide the basis to
the development of computational methods to predictnew DDIs. Recently, many computational methods have
been proposed to predict potential DDIs based on the
assumptionthatsimilardrugstendtointeractwithsimilarother drugs. These approaches usually used the biolog-
ical network data, chemical substructure data and phe-
notypic data. Based on MACCS substructures of drugs,Vilar et al. developed a similarity-based model to pre-
dict new DDIs [ 16]. Liu et al. proposed a model to
predictpotentialDDIsviarandomforest-basedclassifica-tion model, which also adopted a feature selection tech-
nique over the chemical substructures, protein-protein
interactions between targets of drugs and target enrich-
ment of KEGG pathways [ 17]. Cheng et al. proposed a
method to infer novel DDIs via machine learning classi-fiers, whose major feature is integrating drug chemical,
phenotypic and genomic properties [ 18]. IPFs (interac-
tionprofilefingerprints)methodwasproposedtopredicthidden DDIs [ 19]. Logistic regression model was used
to predict new DDIs by Takeda et al., which analyzedthe effects of 2D structural similarities of drugs on DDI
prediction with other pharmacokinetics (PK) and phar-
macodynamics(PD)knowledge[ 20].Viaconstructingthe
drug similarity based on their 2D and 3D molecular sub-structures, targets, side effects and known DDIs, Vilar et
al. further proposed a method to predict new DDIs on
a large scale data, where the key feature is capturing thecharacteristicsofdrugsby3Dsubstructureswhen2Dsub-
structures are missing [ 21]. Herrero-Zazo et al. provided
a computational method to predict DDIs by differenttypes of DDIs and their mechanisms [ 22]. By integrat-
ingsimilaritiesfromdrugmolecularandpharmacological
phenotypes, Li et al. used a Bayesian network to providelarge-scale exploration and analysis of drug combinations
[23]. Through calculating the functional similarity from
drug carriers, drug transporters, drug enzymes and drugtargets, Ferdousi et al. developed an approach to dis-
cover new DDIs [
24]. Based on the Probabilistic Soft
Logicmethod,acomputationalframeworkwasdeveloped
to discover new DDIs by integrating the multiple drug
similarities and known DDIs [ 25]. The label propagation
approachwasalsodevelopedtodiscovernewDDIs,which
used drug chemical structures, side effects and off side
effects [26]. In order to predict drug adverse drug reac-
tions (ADRs), a systems pharmacology model called MEF
(multiple evidence fusion) has been developed by inte-
grating known DDIs and other similarities of drugs [ 27].
Based on the assumption that synergistic effects of drugs
are usually similar, Network-based Laplacian regularized
Least Square Synergistic (NLLSS) method was developedto predict novel DDIs [ 28]. Via calculating the similari-
ties of chemical, biological, phenotypic and known DDIs
of drugs, Zhang et al. proposed three ensemble methodsto predict novel DDIs, which included a weight average
ensemble method and two classifier ensemble methods
(L1andL2)[ 29].
In addition, many other approaches used quantita-
tive structure-activity relationship (QSAR) model, clin-ical data and data mining to study DDIs. Matthews
et al. developed 14 QSAR models to predict the car-
diacadverseeffectsforgenericpharmaceuticalsubstances[30]. Zakharov et al. developed QSAR models to predict
thelikelihoodofDDIsforanypairofdrugsbyradialbasis
functions with self-consistent regression (RBF-SCR) andrandomforest(RF)[ 31].Camietal.proposedaPredictive
Pharmacointeraction Networks (PPINs) to predict novel
DDIs by exploiting the known DDIs and other intrinsicand taxonomic properties of drugs and AEs [ 32]. Huang
et al. developed a method to predict DDIs using protein-
protein interaction network and clinical side effects [ 33].
Based on information of drug metabolism, text-mining
andreasoningmethodsweredevelopedtoinfernewDDIs
[34]. Iyer et al. used the textual portion Electronic health
records(EHRs)todirectlydiscovernewDDIs[ 35].BandaYanetal. BMCBioinformatics 2019,20(Suppl15):538 Page3of10
et al. also adopted a data mining method to predict
new DDIs from the EHRs [ 36]. Based on the k-nearest
neighbor algorithm, Chen et al. proposed a model to
predict DDIs which integrated nine predictors by major-ity voting [ 37]. Furthermore, the drug response predic-
tion and drug-target interaction prediction are also the
important research topics about drugs. By integratinggenomic/pharmaceutical data, protein-protein interac-
tionnetwork,andpriorknowledgeofdrug-targetinterac-
tions with the techniques of network propagation, Wanget al. have developed a dNetFS method to prioritize
genetic and gene expression features of cancer cell lines
that predict drug response [ 38]. Based on the massively
collected drug-kinase interactions and drug sensitivity
datasets, Liu et al. employed a sparse linear model to
infer essential kinases governing the cellular responses todrugtreatmentsincancercells[ 39].Basedonthesequence
information of both targets and drugs, DeepDTA is used
topredictdrug-targetinteractionbindingaffinities,which
isadeep-learningbasedmodel(convolutionalneuralnet-
works)[40].
Although the above DDI prediction methods have
achieved some good prediction results of novel DDIs and
provided useful information for drug development andpractice process. However, these methods did not pay
enough attention to new drugs which do not have any
DDIs with other drugs or cannot predict novel DDIs fornewdrugsbecauseknownDDIsaremissing.
In this study, we develop a computational method
(called DDIGIP) to predict novel DDIs based on drugGaussian interaction profile (GIP) kernel similarity and
regularized least squares (RLS) classifier. We calculate
the GIP similarity of drugs by known DDIs, and thenadopt the RLS method to compute the related scores of
any drug pairs. In addition, when predicting DDIs for
new drugs, we use the KNN method to compute the ini-
tial relational scores by similarity calculated from some
important chemical, biological and phenotypic informa-tion of drugs. The drug chemical structures, drug-target
interactions, drug enzymes, drug transports, drug path-
ways, drug indications, drug side effects and drug offside effects are all used to calculate similarity of drugs.
5-fold cross validation (5CV), 10-fold cross validation
(10CV) and de novo drug validation are used to systemi-callyassesspredictionperformanceofDDIGIP,compared
with other methods. In 5-fold cross validation, the area
under the ROC curve (AUC) value of DDIGIP is 0.9600which is slightly better than the state-of-the-art method
L1 classifier ensemble (L1E) method results of 0.9570. In
addition, the experimental results of 10-fold cross valida-tion also demonstrate that DDIGIP outperforms the L1E
method.Indenovodrugvalidation,DDIGIPachievesthe
AUC of 0.9262, which is also better than the weighted
average ensemble (WAE) method result of 0.9073. Casestudies further validate the prediction ability of DDIGIP
method.
Materials
In this study, the benchmark dataset of DDIs composes
of 548 drugs and 48,584 DDIs. This dataset is obtained
from the TWOSIDES database. In addition, because weneed to calculate the relational scores of new drugs, we
also download other chemical, biological and phenotypic
data from other databases to compute the similarity ofdrugs. The chemical data are PubChem substructures
which are downloaded from the PubChem Compound
database.Biologicaldataincludedrugtargets,drugtrans-
ports, drug enzymes and drug pathways, the first three
types are obtained from the DrugBank database and thelast one is from the KEGG database. Furthermore, the
phenotypic data composes of drug indications, drug side
effects and drug off side effects. The SIDER databaseprovided the drug indications and drug side effects, and
OFFSIDESprovidedthedrugoffsideeffects.
Previous studies also provided the download links for
thesedatasets[ 29].Table1showstherelevantinformation
whichincludesdatatype,datasourceanddimensionality.
Methods
GIPkernelsimilarityofdrugs
The GIP kernel similarity has widely been used in otherprediction issues of similar areas and achieved effective
prediction performances [ 41–46]. RLS-Kron is provided
topredictdrug-targetinteractionsbasedonRLSclassifier
of Kronecker product kernel and GIP kernel similarities
of drugs and targets [ 41]. SDTRLS is provided to predict
drug-targetinteractionsbasedonintegrationsimilarityof
drugGIPkernelsimilarityandchemicalsubstructuresim-
ilaritybytheSNFmethod[ 42,47].LDAPisusedtopredict
lncRNA-disease associations by using a bagging SVM
Table1Thedescriptionofbenchmarkdataset
Data
typeData Database dimensionality
chemical Chemical
substructuresPubChem 881
Biological Drug-targets DrugBank 780
Drugtransporters DrugBank 18Drugenzymes DrugBank 129Drugpathways KEGG 253
Phenotypic Drugindications SIDER 4897
Drugsideeffects SIDER 4897Drugoff
sideeffectsOFFSIDES 9496
Interaction Drug-drug
interactionsTWOSIDES Drugs:548,DDIs:48,584Yanetal. BMCBioinformatics 2019,20(Suppl15):538 Page4of10
classifier based on lncRNA and disease similarities which
include GIP kernel similarity [ 43]. DNRLMF-MDA is an
miRNA-disease associations prediction method based on
dynamicneighborhoodregularizedlogisticmatrixfactor-ization,whichalsousestheGIPkernelsimilarity.
WecomputetheGIPsimilarityofdrugsviaknownDDIs
in this study. We denote D={d
1,d2,......,dN}as the set
ofNdrugs. The known DDIs can be represented by an
adjacency matrix Y∈N∗N. The value of yijis 1 ifdi
anddjhaveaknowninteraction,and0otherwise.TheGIP
kernelsimilaritybetweendrugs dianddjcanbecalculated
asfollows:
Gsim/parenleftbig
di,dj/parenrightbig
=exp/parenleftbig
−γd||ydi−ydj||2/parenrightbig
(1)
γd=γ,
d//parenleftBigg
1
NN/summationdisplay
i=1||ydi||2/parenrightBigg
(2)
where γdis the regularization parameter of kernel band-
width and γ,
dis set to be 1 according to previous studies
[42,44],ydi={yi1,yi2,......,yiN}is the interaction profile
ofdrugdi.
RLSclassifierandpredictiondDIs
The (kernel) RLS classifier is based on the assumption
thatsimilarprincipal(adjuvant)drugsaretendedtointer-
act with the same adjuvant (principal) drug and has beenwidely used in other areas [ 42,48,49]. After calculating
theGIPkernelsimilarity G
sim,weadopttheRLSclassifier
tocomputetheinteractionprobabilityscoresofdrugpairsasfollows:
ˆY
p=Gsim(Gsim+σI)−1Y (3)
YP=ˆYp+ˆYT
p
2(4)
where σis the regularization parameter and set to be 1
according to previous study [ 41]. Furthermore, the Gsim
andIaretheGIPsimilaritymatrixandtheidentitymatrix,
respectively. The Ypis the final prediction result matrix,
which is symmetric. The interacted probabilities of drugpairs are ranked in descending order. A candidate drug
pairwiththerank1isofthemostpossibledrugpair.
KNNfornewdrugs
New drugs have no any known interaction with other
drugs, which makes prediction DDIs for these drugs isimpossible by existing methods. Therefore, we adopt the
KNN method to calculate their initial relational scores
based on the integrated feature similarity of chemical
structure,biologicalandphenotypicinformation.
In order to calculate the integrated feature similarity
S
sim∈N∗N,weadoptthePearsoncorrelationcoefficient
tocomputesimilaritybasedonthebinaryvectorsofdrug
chemical substructures, drug targets, drug transporters,drugenzymes,drugpathways,drugindications,drugsideeffects and drug off side effects. We can see from Table
1 that the total dimensionality of a binary vector of any
drug is 21,351, whose value is 1 when the related feature
ispresentandotherwiseis0.Specifically,thesimilarityofdrugpair d
ianddjiscalculatedasfollows:
Si,j
sim=Cov/parenleftBig
vdi,vdj/parenrightBig
D/parenleftbig
vdi/parenrightbig
D/parenleftBig
vdj/parenrightBig=E/parenleftBig/parenleftbig
vdi−Evdi/parenrightbig/parenleftBig
vdj−Evdj/parenrightBig/parenrightBig
D/parenleftbig
vdi/parenrightbig
D(vdj)(5)
wherevdiandvdjarethefeaturevectorsofdrugs dianddj,
respectively. Covis the covariance. EandDare the math-
ematicalexpectationandstandarddeviation,respectively.
After obtaining the integrated feature similarity Ssim,
we calculate the initial scores of new drugs by the KNN
method. Specifically, the interaction scores YKNN(di,dj)
between new drug diand another drug djcan be calcu-
latedasfollows:
YKNN/parenleftbig
di,dj/parenrightbig
=/summationtextS(i,l)
simylj/summationtextS(i,l)
sim,dl∈Kset (6)
whereS(i,l)
simis the (i,l)-th element of the integrated simi-
laritymatrixand yljisthe(l,j)-thelementofknownDDIs
matrixY∈N∗N.Ksetrepresentsthesetoftop Knearnest
neighbors according to the Ssimmatrix. In this study, we
setthevalueof Kbydenovodrugvalidation.
Algorithm 1 is the description of our DDIGIP method.
As the 0 vectors in the DDIs adjacency matrix Ycorre-
spond to unknown cases, we firstly compute the initialrelational interaction scores for new drugs via the KNN
method which uses the feature similarity S
simof drugs by
integratingchemical,biologicalandphenotypicdata.The
Algorithm1 DDIGIP
Input:Drug set DS, DDIs adjacency matrix Y,a n d
parameter K
Output: predictedassociationmatrix Yp
DDIGIP( DS,Y,K)
1:Searchfordrugset DNew(0vector)thateachdrughas
noknownDDIs;
2:ifDNewisnotnull
3:Calculatefeaturesimilarity SsimofdrugsbyPearson
correlationcoefficient;
4:foriinDNew
5:Calculatethe YKNN(i,:)bytheKNNmethod;
6:Setinitialscoresofdrug dibyYKNN(i,:);
7:end
8:end
9:CalculateGIPsimilarity Gdofdrugs;
10:Basedon GdandY,obtainthepredictionresult Ypby
theRLSmethod;
11:ReturnYp;Yanetal. BMCBioinformatics 2019,20(Suppl15):538 Page5of10
feature similarity Ssimis calculated by Pearson correla-
tioncoefficient.AftercomputingtheGIPsimilarity Gdof
drugs, we take the RLS classifier to calculate the interac-
tionscoresofdrugpairs.ThefinalpredictionresultmatrixisY
p.F igure1demonstratestheworkflowofDDIGIP.
RESULTSaNDdISCUSSIONS
Benchmarkevaluationandevaluationindices
5CV and 10CV are widely used to evaluate the per-
formance for predicting drug-drug interactions [ 28,29],
drug-target interactions [ 42,50], drug-disease inter-
actions [ 51–53], lncRNA-disease associations [ 43,54],
miRNA-disease associations [ 44,55]a n ds oo n .I nt h i s
study, we evaluate the predictive performance of DDIGIP
using5CVand10CV.In5CV,allknownDDIsaredividedinto 5 folds, and each fold, in turn, was left out as the
test set while the rest 4 folds as the training set. In 10CV,
we also divide known DDIs into 10 folds, and each fold istreated as test set in turn, while the remaining 9-folds are
asthetrainingset.Weadopt10repeatsin5CVand10CV.
Furthermore, the actual generalization ability of predict-ing potential DDIs for new drugs is also an important
aspecttoassessthepredictionperformance.Wethuscon-
duct de novo drug validation to evaluate the predictiveperformance of DDIGIP. In de novo drug validation, we
takeknownDDIsofeachdrug,inturn,andtherestDDIs
ofotherdrugsasthetrainingset.
From a prediction method, each drug pair obtains a
prediction score. Then each known interaction betweentwo drugs in the test is ranked relative to the candidateinteractions (all unknown interactions). On a specified
rank threshold, TPR (true positive rate) is the fraction of
known interactions that are correctly predicted, and FPR
(falsepositiverate)isthefractionofunknowninteractionsthat are predicted to be true interactions. The receiver
operatingcharacteristiccurve(ROC)canbedrawnbased
on various TPR and FPR values with various rank thresh-olds.Thenwealsousetheareaunderthereceiveroperat -
ing curve (AUC) to measure the prediction performance
of DDIGIP and other methods. The higher its AUC valueis,thebetterpredictionperformanceamethodachieves.
Comparisonwithpreviousmethods
In this study, we compare our method with other fourmethods: weighted average ensemble (WAE) method, L1
classifier ensemble (L1E) method, L2 classifier ensemble
(L2E) method [ 29] and label propagation (LP) method
[26], with the same validation method in the benchmark
dataset.
5CV
Table2shows that the prediction performances of five
methodsin5CV.BasedontheAUCvaluesofthesemeth-
ods, DDIGIP is slightly better than other methods. Itshows that the GIP similarity is reasonable to use known
DDIs because DDIGIP only uses known DDIs in 5CV.
In addition, three integrating methods (WAE, L1E, L2E)
were also achieved the good results because they inte-
grated the neighbor recommender method, random walkmethodandmatrixperturbationmethod.
Fig.1TheworkflowofDDIGIPYanetal. BMCBioinformatics 2019,20(Suppl15):538 Page6of10
Table2Thepredictionperformancesin5CV,10CVanddenovo
validation,thebestresultsareintheboldface
Theprediction
performances(AUC)
Method Feature 5CV 10CV Denovo
WAE Chemicaldata,
biologicaldata,phenotypicdata0.9502 0.9530 0.9073
L1E Chemicaldata,
biologicaldata,phenotypicdata0.9570 0.9599 ∅
L2E Chemicaldata,
biologicaldata,phenotypicdata0.9561 0.9594 ∅
LPDrug-sub 0.9356 0.9359 0.8993
Drug-Label 0.9364 0.9368 0.8994Drug-OffLabel 0.9374 0.9378 0.8997
DDIGIP Chemicaldata,
biologicaldata,phenotypicdata0.9600 0.9636 0.9262
The∅representsthatwedidnotcomputethepredictionperformancebecausethe
predictionlimitfornewdrugs.
10CV
Table2also shows the prediction performances of five
methods in 10CV. DDIGIP also achieved the best predic-tion result and its AUC value is 0.9636 which is larger
thanothermethodsWAE:0.9530,L1E:0.9599,L2E:0.9594
and LP (max): 0.9378, respectively. By comparing the
prediction performances of DDIGIP in 5CV and 10CV,
DDIGIPismoreeffectivetopredictDDIsin10CVthanin5CV. It proves that DDIGIP has better prediction ability
whentherearemanyknownDDIs.
Denovodrugvalidation
In de novo drug validation, we compare DDIGIP with
LP and WAE. We do not perform the de novo drugvalidationonotherexistingmethodsbecauseoftheirpre-
dictionlimitfornewdrugs.Similartopreviousstudies,we
also obtain the weights of integrated methods (neighborrecommender method and random walk method) with
drug chemical data, biological data and phenotypic data.
Table2shows that DDIGIP also obtains the best predic-
tion performance in terms of AUC (0.9262), compared
with other methods (WAE: 0.9073, LP (max):0.8997). It
alsofurtherindicatesthattheGIPsimilarityiseffectivetouseknownDDIs.
Computationtimecomparison
The computation time is also an important aspect toassesstheperformanceofcomputationalmethods.Inthisstudy, we also compare the average computation time
o ff i v em e t h o d si n5 C V .F i g u r e 2shows that the run-
time of DDIGIP is less than those of other methods. Inaddition, since WAE, L1E and L2E are the integrationmethod, their computation times are longer than those
of LP and DDIGIP. We can see from Fig. 2that DDIGIP
runs the fastest and its computation time is 6.61 seconds
in5CV.
Parameteranalysisfor K
In order to verify the robustness of DDIGIP, we ana-
lyze the parameters Kthat is the number of the near-
est neighbors in de novo drug validation. The optimal
parameter value of Kis selected by the grid search.
Figure3shows the AUC values of DDIGIP under vari-
ation of K ranging from 1 to 15 in de novo validation.
We can see from Fig. 3that the prediction performance
has the ascending trend when K ranges from 1 to 7,
while has the descending trend when K ranges from 11to 15. In addition, DDIGIP has a relatively stable predic-
tion performance and achieves the best prediction result
(AUC:0.9262) when K is 9. It indicates that a reasonablevalue of K can improve the prediction performance of
DDIGIP.
Casestudies
To illustrate the prediction performance of DDIGIP
method, we conduct two types of case studies. The oneincludesthetop20predictedDDIsunderallknownDDIs,
in which the benchmark dataset is obtained from the
TWOSIDES database while the confirmed database is
DrugBanK database. Another includes top 20 the new
DDIsindenovovalidationofdrugRanolazine(DB00243)whose confirmed database composes of TWOSIDES
databaseandDrugBanKdatabase.
We can see from Table 3that 9 out of top 20 DDIs
predictedbyDDIGIParevalidatedinDrugBank.Thever-
ification success rate is 45%. Zafirlukast (DB00549) is an
oral leukotriene receptor antagonist (LTRA) drug usu-ally used in the maintenance treatment of asthma, its
metabolism can be decreased by Rabeprazole (DB01129)
[56,57]. Atazanavir (DB01072) is an antiretroviral drug
of the protease inhibitor (PI) class, which is used to treat
infection of human immunodeficiency virus (HIV) and
its metabolism can be decreased when combining withAmlodipine (DB00381) [ 8,58]. In addition, Pantoprazole
(DB00213) also decreases the metabolism of Methadone
(DB00333)[ 59] .T h er i s ko rs e v e r i t yo fa d v e r s ee f f e c t s
can be increased when Atenolol (DB00335) is combined
withNadolol(DB01203),Clotrimazole(DB00257)iscom-bined with Pregabalin (DB00230) or Enalapril (DB00584)
is combined with Perindopril (DB00790) [ 9,10,60,61].
The hypotensive activities of Nadolol (DB01203) can beincreased by Propranolol (DB00571) [ 62]. The absorp-
tion of Cefpodoxime (DB01416) can be decreased when
combining with Ranitidine (DB00863) [ 63]. Acebutolol
(DB01193) also increases the serum concentration of
Metoprolol(DB00264)[ 64].Yanetal. BMCBioinformatics 2019,20(Suppl15):538 Page7of10
Fig.2Theaveragecomputationtimesoffivemethodsin5-foldcrossvalidation
Ranolazine is an antianginal medication used in the
treatment of chronic angina [ 10]. Table 4shows that
top 20 predicted DDIs of Ranolazine are validated in
TWOSIDES database or DrugBanK database. In addi-tion, 12 out of top 20 DDIs are simultaneously confirmed
by TWOSIDES database and DrugBanK database, while
the rest are confirmed by one of them. For example,the metabolism of Levothyroxine (DB00451) and Zolpi-
dem (DB00425) can be decreased when combining with
Ranolazine [ 15,56]. Clopidogrel is an antiplatelet agent
structurally and pharmacologically similar to ticlopi-dine, which is used to inhibit blood clots in a vari-
ety of conditions such as peripheral vascular disease,
coronary artery disease, and cerebrovascular disease [ 8].
Fig.3TheAUCofDDIGIPunderdifferentsettingsof Kindenovodrugvalidation,thesign∗representsthedefaultvalueYanetal. BMCBioinformatics 2019,20(Suppl15):538 Page8of10
Table3Top20newDDIspredictedbyDDIGIPmethod
Rank DrugID1 DrugID2 Evidence
1 DB00448 DB01059 Unknown
2 DB00549 DB01129 DrugBank3 DB00991 DB00231 Unknown4 DB00470 DB00331 Unknown5 DB00630 DB00346 Unknown6 DB00863 DB01416 DrugBank7 DB01203 DB00335 DrugBank8 DB00813 DB00535 Unknown9 DB00257 DB00230 DrugBank10 DB00806 DB01036 Unknown11 DB00927 DB01193 Unknown12 DB00333 DB00213 DrugBank13 DB00987 DB00758 Unknown14 DB01595 DB01137 Unknown15 DB06151 DB01068 Unknown16 DB00328 DB00218 Unknown17 DB00264 DB01193 DrugBank18 DB01072 DB00381 DrugBank19 DB01203 DB00571 DrugBank20 DB00584 DB00790 DrugBank
Table4Thevalidationresultoftop20newDDIsofdrug
Ranolazine(DB00243)predictedbyDDIGIPmethodindenovovalidation
Rank DrugID1 DrugID2 Evidence
1 DB00243 DB00451 TWOSIDES,DrugBanK
2 DB00338 TWOSIDES,DrugBanK3 DB00641 TWOSIDES,DrugBanK4 DB00945 TWOSIDES,DrugBanK5 DB00758 TWOSIDES,DrugBanK6 DB00316 DrugBanK7 DB00264 TWOSIDES8 DB00695 TWOSIDES9 DB00722 TWOSIDES10 DB00390 TWOSIDES,DrugBanK11 DB00448 TWOSIDES,DrugBanK12 DB00999 TWOSIDES13 DB00863 TWOSIDES,DrugBanK14 DB00630 TWOSIDES15 DB00635 DrugBanK16 DB00213 TWOSIDES,DrugBanK17 DB00678 TWOSIDES,DrugBanK18 DB00425 TWOSIDES,DrugBanK19 DB00177 TWOSIDES20 DB00331 TWOSIDES,DrugBanKThe serum concentration of Clopidogrel (DB00758) can
be increased when combining with Ranolazine [ 15]. Sim-
ilarly,theserumconcentrationofSimvastatin(DB00641),
Acetylsalicylic (DB00945) or Metformin (DB00331) alsocan be increased when combining with Ranolazine
[56,65]. In addition, when Ranolazine is combined with
Omeprazole(DB00338)orAcetaminophen(DB00316),itsserumconcentrationalsocanbeincreased[ 15,66].
Conclusion
In this study, we have proposed a computational method,
calledDDIGIP,forDDIsprediction.TheGIPsimilarityof
drugs is calculated by the known DDIs, which makes full
u s eo fk n o w nD D I s .T oo u rk n o w l e d g e ,i nt h ep r e v i o u s
studies the RLS-Kron method is used to predict interac-tionofbipartitenetworks,suchasdrug-targetinteraction
networks, drug-disease interaction network and so on.
Experiments are conducted using two different types ofcrossvalidations:5-foldcrossvalidationand10-foldcross
validation. The prediction ability of DDIGIP has been
illustrated by comparing it with four other competingstate-of-the-artmethods.
Furthermore, based on Pearson correlation coefficient,
we obtain a comprehensive feature similarity of drugs byintegrating the chemical, biological and phenotypic data
into a high dimension binary vector. In order to more
effectively predict DDIs for new drugs, we also conductde novo drug validation. We add a preprocessing step,
KNN, to compute the initial relational scores according
to the feature similarity of drugs. Because the vector 0
in the matrix corresponding to unknown cases or miss-
ing values rather than confirmed non-interactions, thepreprocessingcanimprovethepredictionperformance.
Despite the advantages of DDIGIP as discussed above,
it still has some limitations. The more effective methodshould be developed to integrate known DDIs with other
chemical, biological and phenotypic data. In addition,
othernewpredictionmethodssuchasmatrixcompletion[67], deep learning [ 68] and interpretable boosting model
[69]couldbeconsidered.Finally,inthisstudy,thebench-
mark dataset of DDIs only includes the positive samplesand is an imbalanced dataset, we will also consider some
other methods (SVM [ 70],LibD3C [ 71],extreme learning
machine [ 72] and collaborative metric learning [ 73]) to
predict DDIs when we obtain reliable negative samples in
thefuture.Weexpecttodevelopamoreeffectivemethod
to predict DDIs by overcoming these limitations in thefuture.
Abbreviations
10CV:10-foldcrossvalidation;5CV:5-foldcrossvalidation;AUC:Areaunderthereceiveroperatingcurve;DDI:Drug-druginteraction;GIP:Gaussianinteractionprofile;KNN:K-nearestneighbors;L1E:L1Classifierensemblemethod;L2E:L2Classifierensemblemethod;LP:Labelpropagation;RLS:Regularizedleastsquaresclassifier;WAE:WeightedaverageensemblemethodYanetal. BMCBioinformatics 2019,20(Suppl15):538 Page9of10
Acknowledgements
Theauthorsareverygratefultotheanonymousreviewersfortheirconstructivecommentswhichhavehelpedsignificantlyinrevisingthiswork.TheauthorswouldliketoexpresstheirgratitudeforthesupportfromtheNationalNaturalScienceFoundationofChina(No.61772552,No.61420106009andNo.61832019),111Project(No.B18059)andHunanProvinvialScienceandTechnologyProgram(No.2018WK4001).
Aboutthissupplement
ThisarticlehasbeenpublishedaspartofBMCBioinformatics,Volume20Supplement15,2019:Selectedarticlesfromthe14thInternationalSymposiumonBioinformaticsResearchandApplications(ISBRA-18):bioinformatics.Thefullcontentsofthesupplementareavailableat https://bmcbioinformatics.
biomedcentral.com/articles/supplements/volume-20-supplement-15
Authors’contributions
JWconceivedtheproject;CYandGDdesignedtheexperiments;CYperformedtheexperiments;CY,GDandFXWwrotethepaper.Allauthorsreadandapprovedthefinalmanuscript.
Funding
PublicationcostsarefundedbyNationalNaturalScienceFoundationofChinaunderGrantNo.61420106009.
Availabilityofdataandmaterials
TheuseddataisprovidedbyZhang etal.[29].Pleasedownloadthedatafrom
https://github.com/zw9977129/drug-drug-interaction/ orcontacttheauthors
fordatarequests.
Ethicsapprovalandconsenttoparticipate
Notapplicable.
Consentforpublication
Notapplicable.
Competinginterests
Theauthorsdeclarethattheyhavenocompetinginterests.
Authordetails
1SchoolofComputerScienceandEngineering,CentralSouthUniversity,932
SouthLushanRd,410083,ChangSha,China.2SchoolofComputerand
Information,QiannanNormalUniversityforNationalities,LongshanRoad,558000,DuYun,China.
3DepartmentofComputerScience,GeorgiaState
University, GA30302,Atlanta,USA.4BiomedicalEngineeringandDepartment
ofMechanicalEngineering,UniversityofSaskatchewan, SKS7N5A9,Saskatoon,Canada.
Received:31August2019 Accepted:10September2019
Published:24December2019
References
1. CrowtherNR, HolbrookAM, KenwrightR, KenwrightM.Drug
interactionsamongcommonlyusedmedications.chartsimplifiesdatafromcriticalliteraturereview.CanFamPhys.1997;43:1972.
2. VenkatakrishnanK, vonMoltkeLL, ObachR, GreenblattDJ.Drug
metabolismanddruginteractions:applicationandclinicalvalueofinvitromodels.CurrDrugMetabolism.2003;4(5):423–59.
3. QuinnD, DayR.Druginteractionsofclinicalimportance.DrugSafety.
1995;12(6):393–452.
4. OnakpoyaIJ, HeneghanCJ, AronsonJK.Post-marketingwithdrawalof
anti-obesitymedicinalproductsbecauseofadversedrugreactions:asystematicreview.BMCMed.2016;14(1):191.
5. CDC.Health,UnitedStates,2014(5/2015)-hus14.pdf. http://www.cdc.
gov/nchs/data/hus/hus14.pdf .Accessed15Nov2017.
6. NahtaR, HungM-C, EstevaFJ.Theher-2-targetingantibodies
trastuzumabandpertuzumabsynergisticallyinhibitthesurvivalofbreastcancercells.CancerRes.2004;64(7):2343–6.
7. ChouT-C.Drugcombinationstudiesandtheirsynergyquantification
usingthechou-talalaymethod.CancerRes.2010;70(2):440–6.8. WishartDS, KnoxC, GuoAC, ShrivastavaS, HassanaliM, StothardP,
ChangZ, WoolseyJ.Drugbank:acomprehensiveresourceforinsilicodrugdiscoveryandexploration.NucleicAcidsRes.2006;34(suppl_1):668–72.
9. KnoxC, LawV, JewisonT, LiuP, LyS, FrolkisA, PonA, BancoK, MakC,
NeveuV,etal.Drugbank3.0:acomprehensiveresourcefor’omics’researchondrugs.NucleicAcidsRes.2010;39(suppl_1):1035–41.
10. LawV, KnoxC, DjoumbouY, JewisonT, GuoAC, LiuY, MaciejewskiA,
ArndtD, WilsonM, NeveuV,etal.Drugbank4.0:sheddingnewlightondrugmetabolism.NucleicAcidsRes.2013;42(D1):1091–7.
11. WangY, XiaoJ, SuzekTO, ZhangJ, WangJ, BryantSH.Pubchem:a
publicinformationsystemforanalyzingbioactivitiesofsmallmolecules.NucleicAcidsRes.2009;37(suppl_2):623–33.
12. KuhnM, CampillosM, LetunicI, JensenLJ, BorkP.Asideeffectresource
tocapturephenotypiceffectsofdrugs.MoleSystBiol.2010;6(1):343.
13. TatonettiNP, PatrickPY, DaneshjouR, AltmanRB.Data-drivenprediction
ofdrugeffectsandinteractions.SciTransMed.2012;4(125):125–31.
14. KanehisaM, GotoS, FurumichiM, TanabeM, HirakawaM.Keggfor
representationandanalysisofmolecularnetworksinvolvingdiseasesanddrugs.NucleicAcidsRes.2009;38(suppl_1):355–60.
15. PoluzziE, RaschiE, MorettiU, DePontiF.Drug-inducedtorsadesdepointes:
dataminingofthepublicversionofthefdaadverseeventreportingsystem(aers).PharmacoepidemiolDrugSafety.2009;18(6):512–8.
16. VilarS, HarpazR, UriarteE, SantanaL, RabadanR, FriedmanC.
Drug-druginteractionthroughmolecularstructuresimilarityanalysis.JAmMedInfAssoc.2012;19(6):1066–74.
17. LiuL, ChenL, ZhangY.-H., WeiL, ChengS, KongX, ZhengM, HuangT,
CaiY-D.Analysisandpredictionofdrug–druginteractionbyminimumredundancymaximumrelevanceandincrementalfeatureselection.JBiomoleStructDynamics.2017;35(2):312–29.
18. ChengF, ZhaoZ.Machinelearning-basedpredictionofdrug–drug
interactionsbyintegratingdrugphenotypic,therapeutic,chemical,andgenomicproperties.JAmMedInfAssoc.2014;21(e2):278–86.
19. VilarS, UriarteE, SantanaL, TatonettiNP, FriedmanC.Detectionof
drug-druginteractionsbymodelinginteractionprofilefingerprints.PloSone.2013;8(3):58321.
20. TakedaT, HaoM, ChengT, BryantSH, WangY.Predictingdrug–drug
interactionsthroughdrugstructuralsimilaritiesandinteractionnetworksincorporatingpharmacokineticsandpharmacodynamicsknowledge.JCheminforma.2017;9(1):16.
21. VilarS, UriarteE, SantanaL, FriedmanC, PTatonettiN.Stateoftheartand
developmentofadrug-druginteractionlargescalepredictorbasedon3dpharmacophoricsimilarity.CurrDrugMetabolism.2014;15(5):490–501.
22. Herrero-ZazoM, Segura-BedmarI, HastingsJ, MartínezP.Dinto:using
owlontologiesandswrlrulestoinferdrug–druginteractionsandtheirmechanisms.JChemInfModeling.2015;55(8):1698–707.
23. LiP, HuangC, FuY, WangJ, WuZ, RuJ, ZhengC, GuoZ, ChenX,
ZhouW,etal.Large-scaleexplorationandanalysisofdrugcombinations.Bioinformatics.2015;31(12):2007–16.
24. FerdousiR, SafdariR, OmidiY.Computationalpredictionofdrug-drug
interactionsbasedondrugsfunctionalsimilarities.JBiomedInforma.2017;70:54–64.
25. SridharD, FakhraeiS, GetoorL.Aprobabilisticapproachforcollective
similarity-baseddrug–druginteractionprediction.Bioinformatics.2016;32(20):3175–82.
26. ZhangP, WangF, HuJ, SorrentinoR.Labelpropagationpredictionof
drug-druginteractionsbasedonclinicalsideeffects.SciRep.2015;5:12339.
27. CaoD-S, XiaoN, LiY-J, ZengW-B, LiangY-Z, LuA-P, XuQ-S, ChenA.
Integratingmultipleevidencesourcestopredictadversedrugreactionsbasedonasystemspharmacologymodel.CPT:PharmacomSystPharmacol.2015;4(9):498–506.
28. ChenX, RenB, ChenM, WangQ, ZhangL, YanG.Nllss:predicting
synergisticdrugcombinationsbasedonsemi-supervisedlearning.PLoSComputBiol.2016;12(7):1004975.
29. ZhangW, ChenY, LiuF, LuoF, TianG, LiX.Predictingpotential
drug-druginteractionsbyintegratingchemical,biological,phenotypicandnetworkdata.BMCbioinformatics.2017;18(1):18.
30. MatthewsEJ, FridAA.Predictionofdrug-relatedcardiacadverseeffects
inhumans-a:Creationofadatabaseofeffectsandidentificationoffactorsaffectingtheiroccurrence.RegToxicolPharmacol.2010;56(3):247–75.Yanetal. BMCBioinformatics 2019,20(Suppl15):538 Page10of10
31. ZakharovAV, VarlamovaEV, LaguninAA, DmitrievAV, MuratovEN,
FourchesD, Kuz’minVE, PoroikovVV, TropshaA, NicklausMC.Qsarmodelingandpredictionofdrug–druginteractions.MolePharma.2016;13(2):545–56.
32. CamiA, ManziS, ArnoldA, ReisBY.Pharmacointeractionnetworkmodels
predictunknowndrug-druginteractions.PloSone.2013;8(4):61468.
33. HuangH, ZhangP, QuXA, SanseauP, YangL.Systematicpredictionof
drugcombinationsbasedonclinicalside-effects.SciRep.2014;4:7160.
34. TariL, AnwarS, LiangS, CaiJ, BaralC.Discoveringdrug–drug
interactions:atext-miningandreasoningapproachbasedonpropertiesofdrugmetabolism.Bioinformatics.2010;26(18):547–53.
35. IyerSV, HarpazR, LePenduP, Bauer-MehrenA, ShahNH.Miningclinical
textforsignalsofadversedrug-druginteractions.JAmMedInformaAssoc.2014;21(2):353–62.
36. BandaJM, CallahanA, WinnenburgR, StrasbergHR, CamiA, ReisBY,
VilarS, HripcsakG, DumontierM, ShahNH.Feasibilityofprioritizingdrug–drug-eventassociationsfoundinelectronichealthrecords.DrugSafety.2016;39(1):45–57.
37. ChenL, ChuC, ZhangY-H, ZhengM, ZhuL, KongX, HuangT.
Identificationofdrug-druginteractionsusingchemicalinteractions.CurrBioinforma.2017;12(6):526–34.
38. WangJ, KribelbauerJ, RabadanR.Networkpropagationrevealsnovel
featurespredictingdrugresponseofcancercelllines.CurrBioinforma.2016;11(2):203–10.
39. LiuH, LuoL, ChengZ, SunJ, GuanJ, ZhengJ, ZhouS.Group-sparse
modelingdrug-kinasenetworksforpredictingcombinatorialdrugsensitivityincancercells.CurrBioinforma.2018;13(5):437–43.
40. ÖztürkH, ÖzgürA, OzkirimliE.Deepdta:deepdrug–targetbinding
affinityprediction.Bioinformatics.2018;34(17):821–9.
41. vanLaarhovenT, NabuursSB, MarchioriE.Gaussianinteractionprofile
kernelsforpredictingdrug–targetinteraction.Bioinformatics.2011;27(21):3036–43.
42. YanC, WangJ, LanW, WuF-X, PanY.Sdtrls:Predictingdrug-target
interactionsforcomplexdiseasesbasedonchemicalsubstructures.Complexity.2017;2017(ArticleID2713280):10.
43. LanW, LiM, ZhaoK, LiuJ, WuF-X, PanY, WangJ.Ldap:awebserverfor
lncrna-diseaseassociationprediction.Bioinformatics.2016;33(3):458–60.
44. YanC, WangJ, NiP, LanW, WuFX, PanY.Dnrlmf-mda:predicting
microrna-diseaseassociationsbasedonsimilaritiesofmicrornasanddiseases.IEEE/ACMTransComputBiolBioinforma.2019;16(1):233–43.
45. YanC, DuanG, WuF, PanY, WangJ.Brwmda:Predicting
microbe-diseaseassociationsbasedonsimilaritiesandbi-randomwalkondiseaseandmicrobenetworks.IEEE/ACMTransComputBiolBioinforma.2019.https://doi.org/10.1109/TCBB.2019.2907626 .(tobepublished).
46. YanC, DuanG, WuF, PanY, WangJ.Mchmda:Predicting
microbe-diseaseassociationsbasedonsimilaritiesandlow-rankmatrixcompletion.IEEE/ACMTransComputBiolBioinforma.2019. https://doi.
org/10.1109/TCBB.2019.2926716 .(tobepublished).
47. WangB, MezliniAM, DemirF, FiumeM, TuZ, BrudnoM, Haibe-KainsB,
GoldenbergA.Similaritynetworkfusionforaggregatingdatatypesonagenomicscale.NatMethods.2014;11(3):333.
48. XiaZ, WuL-Y, ZhouX, WongST.Semi-superviseddrug-protein
interactionpredictionfromheterogeneousbiologicalspaces.BMCSystBiol.2010;4(2):S6.
49. YanC, WangJ, WuF-X.Dwnn-rls:regularizedleastsquaresmethodfor
predictingcircrna-diseaseassociations.BMCbioinformatics.2018;19(19):520.
50. WuZ, ChengF, LiJ, LiW, LiuG, TangY.Sdtnbi:anintegratednetwork
andchemoinformaticstoolforsystematicpredictionofdrug–targetinteractionsanddrugrepositioning.BriefBioinforma.2016;18(2):333–47.
51. LuoH, WangJ, LiM, LuoJ, PengX, WuF-X, PanY.Drugrepositioning
basedoncomprehensivesimilaritymeasuresandbi-randomwalkalgorithm.Bioinformatics.2016;32(17):2664–71.
52. LuoH, LiM, WangS, LiuQ, LiY, WangJ.Computationaldrug
repositioningusinglow-rankmatrixapproximationandrandomizedalgorithms.Bioinformatics.2018;34(11):1904–12.
53. LuoH, WangJ, LiM, LuoJ, NiP, ZhaoK, WuFX, PanY.Computational
drugrepositioningwithrandomwalkonaheterogeneousnetwork.IEEE/ACMTransComputBiolBioinforma.2018. https://doi.org/10.1109/
TCBB.2018.2832078 .(tobepublished).54. LuC, YangM, LuoF, WuF-X, LiM, PanY, LiY, WangJ.Predictionof
lncrna-diseaseassociationsbasedoninductivematrixcompletion.Bioinformatics.2018;34(19):3357–64.
55. LanW, WangJ, LiM, LiuJ, WuF-X, PanY.Predictingmicrorna-disease
associationsbasedonimprovedmicrornaanddiseasesimilarities.IEEE/ACMTransComputBiolBioinforma.2018;15(6):1774–82.
56. WishartDS, FeunangYD, GuoAC, LoEJ, MarcuA, GrantJR, SajedT,
JohnsonD, LiC, SayeedaZ,etal.Drugbank5.0:amajorupdatetothedrugbankdatabasefor2018.NucleicAcidsRes.2017;46(D1):1074–82.
57. BhattacharyaA, BandichhorR.Greentechnologiesinthegeneric
pharmaceuticalindustry.GreenChemPharmaInd.2010304–6.
58. MaussS, KlinkerH.Drug-druginteractionsinthetreatmentofhcvamong
peoplewhoinjectdrugs.ClinInfdiseases.2013;57(suppl_2):125–8.
59. WelageLS, BerardiRR.Evaluationofomeprazole,lansoprazole,
pantoprazole,andrabeprazoleinthetreatmentofacid-relateddiseases.JAmPharmaAssoc1996.2000;40(1):52–62.
60. VítovecJ, ŠpinarJ.First-dosehypotensionafterangiotensin-converting
enzyme(ace)inhibitorsinchronicheartfailure:acomparisonofenalaprilandperindopril.EurJHeartFail.2000;2(3):299–304.
61. BurmeisterWE, ReynoldsRD, LeeRJ.Limitationofmyocardialinfarctsize
byatenolol,nadololandpropranololindogs.EurJPharmacol.1981;75(1):7–10.
62. ReevesRA, FromGL, PaulW, LeenenFH.Nadolol,propranolol,and
thyroidhormones:Evidenceforamembrane-stabilizingactionofpropranolol.ClinPharmacolTherap.1985;37(2):157–61.
63. UCHIDAE, OGUCHIK, HISAOKAM, KOBAYASHIS, KAIK, YASUHARAH.
Effectsofranitidine,metoclopromide,andanisotropinemethylbromideontheavailabilityofcefpodoximeproxetil(cs-807)injapanesehealthysubjects.Rinshoyakuri/JapanJClinPharmacolTherap.1988;19(3):573–9.
64. El-BeqqaliA, KussakA, BlombergL, Abdel-RehimM.Microextractionin
packedsyringe/liquidchromatography/electrospraytandemmassspectrometryforquantificationofacebutololandmetoprololinhumanplasmaandurinesamples.JLiquidChromatogrRelTechnol.2007;30(4):575–86.
65. FlorentinM, ElisafMS.Simvastatininteractionswithotherdrugs.Exp
OpinDrugSafety.2012;11(3):439–44.
66. TreygerG, SilverSA, SakharovaAA.Pheochromocytomadiagnosisafter
anabnormalstresstest:Casereportandreviewoftheliterature.J.2015;115(7):3.
67. YangM, LuoH, LiY, WangJ.Drugrepositioningbasedonbounded
nuclearnormregularization.Bioinformatics.2019;35(14):i455–63. https://
doi.org/10.1093/bioinformatics/btz331 .(tobepublished).
68. LiuJ, PanY, LiM, ChenZ, TangL, LuC, WangJ.Applicationsofdeep
learningtomriimages:Asurvey.BigDataMiningAnal.2018;1(1):1–18.
69. LiuL, YuY, FeiZ, LiM, WuF-X, LiH-D, PanY, WangJ.Aninterpretable
boostingmodeltopredictsideeffectsofanalgesicsforosteoarthritis.BMCSystBiol.2018;12(6):105.
70. ChangC-C, LinC-J.Libsvm:alibraryforsupportvectormachines.ACM
TransIntellSystTechnol(TIST).2011;2(3):27.
71. LinC, ChenW, QiuC, WuY, KrishnanS, ZouQ.Libd3c:ensemble
classifierswithaclusteringanddynamicselectionstrategy.Neurocomputing.2014;123:424–35.
72. WangH, WangJ, ZhouL.Asurvivalensembleofextremelearning
machine.ApplIntell.2018;48(7):1846–58.
73. LuoH, WangJ, YanC, LiM, FangxiangW, YiP.Anoveldrug
repositioningapproachbasedoncollaborativemetriclearning.IEEE/ACMTransComputBiolBioinforma.2019. https://doi.org/10.1109/TCBB.2019.
2926453.(tobepublished).
Publisher’sNote
SpringerNatureremainsneutralwithregardtojurisdictionalclaimsin
publishedmapsandinstitutionalaffiliations.